Goldman Sachs Starts Medivation (MDVN) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Broadcom rises 3% on OpenAI custom "Jalapeño" chip reveal
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Xtandi Congressional Letter and CFO Change a Modest Negative at Worst for Medivation (MDVN) - UBS
March 29, 2016 8:38 AM EDTUBS Analyst, Matthew Roden, sees the Medivation (NASDAQ: MDVN) CFO change as a positive and the Congressional letter threatening Xtandi pricing as a modest negative at worst. No change to Buy rating or $50 PT.
In the short term, the transition may lessen the recent acquisition premium that followed media M&A speculation, but adding a deal-oriented CFO to the management team could... More
After-Hours Stock Movers 03/28: (FL) (DCT) (ALDR) Higher; (ALXA) (GEVO) (PBYI) Lower (more...)
March 28, 2016 6:11 PM EDTAlexza Pharmaceuticals Inc. (NASDAQ: ALXA) 49.7% LOWER; warns it may shut-down if it is unable to source additional capital.
Gevo, Inc. (Nasdaq: GEVO) 21.7% LOWER; announced that it intends to offer and sell, subject to market and other conditions, Series C units, with each Series C unit consisting of one share of common stock, Series F warrants to purchase a certain number of shares of common stock and Series H warrants to purchase a certain number of... More
Members of Congress Ask NIH and HHS to Examine Xtandi Pricing (MDVN) - CNBC
March 28, 2016 4:41 PM EDTEleven members of Congress asked NIH and HHS to examine Xtandi pricing, according to CNBC, citing a letter. The headline sent shares of Medivation (Nasdaq: MDVN) sharply lower after-hours.
12 congressmen ask NIH, HHS to examine $MDVN's Xtandi pricing. Letter here: https://t.co/kaodTemjvc
Meg Tirrell (@megtirrell) March 28, 2016... More